Home > Insider Trading > Filing (0001209191-16-111237)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	C/O Longitude Capital Partners Ii, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94025		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	33,064	$13.50	7,467,694	No	4	P	Indirect	By Longitude Venture Partners II, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	45,440	$14.15	7,513,134	No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Longitude Venture Partners II, L.P.
No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Footnotes

Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $12.90 to $13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
The shares are held by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II and in his capacity as such may be deemed to exercise shared voting and investment power over the shares held by Longitude Venture II. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $13.90 to $14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.